Plain-English translation of NCT06301165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer chemotherapy combination called TPC (which includes paclitaxel, cisplatin, and capecitabine) works better than the standard chemotherapy combination GP (gemcitabine and cisplatin) for treating advanced nasopharyngeal cancer. Both groups will receive their assigned chemotherapy drugs first, followed by radiation therapy to the tumor area. Researchers want to see which combination helps patients live longer and causes fewer side effects.
Current treatment guidelines recommend chemotherapy followed by radiation for advanced nasopharyngeal cancer, but doctors aren't sure which chemotherapy combination works best. This medication uses a newer form of paclitaxel that may stay in tumor tissue longer, so this trial will directly compare it to the standard treatment to see if it offers better results.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive your assigned chemotherapy combination (either TPC or GP) given intravenously over several weeks in 3 cycles. After chemotherapy, you will receive concurrent chemoradiotherapy—meaning you'll receive additional chemotherapy while also undergoing intensive radiation therapy directed at your tumor and surrounding lymph nodes. The entire treatment typically lasts several months, with regular visits to the hospital or cancer center for drug infusions, radiation sessions, and blood tests to monitor your health and side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China